NO20041560L - 1,6-nafthyridinderivater som antidiabetiske midler - Google Patents

1,6-nafthyridinderivater som antidiabetiske midler

Info

Publication number
NO20041560L
NO20041560L NO20041560A NO20041560A NO20041560L NO 20041560 L NO20041560 L NO 20041560L NO 20041560 A NO20041560 A NO 20041560A NO 20041560 A NO20041560 A NO 20041560A NO 20041560 L NO20041560 L NO 20041560L
Authority
NO
Norway
Prior art keywords
antidiabetic agents
naphthyridine derivatives
naphthyridine
derivatives
antidiabetic
Prior art date
Application number
NO20041560A
Other languages
English (en)
Norwegian (no)
Inventor
William H Bullock
Yamin Wang
Libing Chen
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of NO20041560L publication Critical patent/NO20041560L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
NO20041560A 2001-09-26 2004-04-16 1,6-nafthyridinderivater som antidiabetiske midler NO20041560L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32451101P 2001-09-26 2001-09-26
PCT/US2002/030376 WO2003027113A1 (fr) 2001-09-26 2002-09-23 Derives de 1,6-naphthyridine et leur utilisation dans le traitement du diabete et de troubles associes

Publications (1)

Publication Number Publication Date
NO20041560L true NO20041560L (no) 2004-05-11

Family

ID=23263913

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20041560A NO20041560L (no) 2001-09-26 2004-04-16 1,6-nafthyridinderivater som antidiabetiske midler
NO20041567A NO20041567L (no) 2001-09-26 2004-04-16 1,8-nafthyridinderivater som antidiabetiske midler

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20041567A NO20041567L (no) 2001-09-26 2004-04-16 1,8-nafthyridinderivater som antidiabetiske midler

Country Status (24)

Country Link
US (5) US6677352B1 (fr)
EP (2) EP1432710A1 (fr)
JP (2) JP2005504807A (fr)
KR (2) KR20040041177A (fr)
CN (2) CN1578781A (fr)
AR (2) AR037504A1 (fr)
BR (2) BR0212829A (fr)
CA (2) CA2463039A1 (fr)
CO (2) CO5560611A2 (fr)
EC (2) ECSP045081A (fr)
GT (2) GT200200191A (fr)
HN (1) HN2002000275A (fr)
HR (2) HRP20040317A2 (fr)
HU (2) HUP0401889A2 (fr)
IL (2) IL160707A0 (fr)
MA (2) MA26344A1 (fr)
MX (2) MXPA04002136A (fr)
NO (2) NO20041560L (fr)
PE (2) PE20030601A1 (fr)
PL (2) PL369567A1 (fr)
RU (2) RU2004112787A (fr)
UY (2) UY27457A1 (fr)
WO (2) WO2003027112A1 (fr)
ZA (2) ZA200403063B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040041177A (ko) * 2001-09-26 2004-05-14 바이엘 파마슈티칼스 코포레이션 당뇨병 치료제로서의 1,6-나프티리딘 유도체
AU2003214879B2 (en) * 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
WO2005018567A2 (fr) * 2003-08-22 2005-03-03 Bayer Pharmaceuticals Corporation Composes et compositions pour le traitement du diabete et de troubles lies au diabete
DE602004024814D1 (de) * 2003-11-04 2010-02-04 Merck & Co Inc Substituierte naphthyridinonderivate
EP1734963A4 (fr) 2004-04-02 2008-06-18 Merck & Co Inc Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
FR2874922A1 (fr) * 2004-07-30 2006-03-10 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
WO2006024741A2 (fr) * 2004-07-30 2006-03-09 Palumed S.A. Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP1916896A4 (fr) * 2005-08-26 2010-08-11 Univ California Antiandrogenes non steroidiens
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenese induite par le recepteur 5ht
WO2008030651A1 (fr) 2006-09-08 2008-03-13 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008074068A1 (fr) * 2006-12-20 2008-06-26 Prana Biotechnology Limited Dérivés de quinoline substitués utilisés comme agents non-amyloïdogéniques
JP5363350B2 (ja) * 2007-03-19 2013-12-11 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
US10017827B2 (en) 2007-04-04 2018-07-10 Nidera S.A. Herbicide-resistant sunflower plants with multiple herbicide resistant alleles of AHASL1 and methods of use
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP2321341B1 (fr) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2448938B9 (fr) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones comme inhibiteurs de pi3k
WO2011075643A1 (fr) 2009-12-18 2011-06-23 Incyte Corporation Dérivés condensés d'hétéroaryles substitués à titre d'inhibiteurs de pi3k
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2558463A1 (fr) 2010-04-14 2013-02-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de i3
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
CA2826649C (fr) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Nouveaux derives d'azabenzimidazole cyclique utiles en tant qu'agents antidiabetiques
WO2012125629A1 (fr) 2011-03-14 2012-09-20 Incyte Corporation Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
CA2839395A1 (fr) * 2011-07-12 2013-01-17 F. Hoffmann-La Roche Ag Composes d'aminomethyl-quinolone
KR102030609B1 (ko) 2011-09-02 2019-10-11 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
CN103183676B (zh) * 2013-03-12 2015-04-08 中国医学科学院医药生物技术研究所 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用
JP2016512507A (ja) 2013-03-13 2016-04-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヒト免疫不全ウイルス複製の阻害剤
EP2970119B1 (fr) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
JO3442B1 (ar) * 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015191677A1 (fr) 2014-06-11 2015-12-17 Incyte Corporation Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k
DK3831833T3 (da) 2015-02-27 2022-11-14 Incyte Holdings Corp Fremgangsmåder til fremstillingen af en pi3k-inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Formes cristallines d'un inhibiteur de pi3k
CN108026113A (zh) 2015-08-10 2018-05-11 Viiv保健英国第五有限公司 作为人免疫缺陷病毒复制的抑制剂的咪唑并吡啶大环类化合物
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EA038455B1 (ru) * 2016-10-26 2021-08-31 Новартис Аг Новые производные нафтиридинона и их применение в лечении аритмии
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (fr) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
CN119258070A (zh) 2018-06-01 2025-01-07 因赛特公司 治疗pi3k相关病症的给药方案
CN110981869A (zh) * 2019-12-10 2020-04-10 天津科技大学 一种1,8-双氮杂色酮的合成方法及其在抗糖尿病药物中的应用
KR102660894B1 (ko) * 2021-09-17 2024-04-26 기초과학연구원 피리미딘-2-아민 화합물의 제조방법
WO2024233847A2 (fr) * 2023-05-10 2024-11-14 Vigil Neuroscience, Inc. Composés hétérocycliques utilisés en tant que récepteur de déclenchement exprimé sur des agonistes de cellules myéloïdes 2 et procédés d'utilisation

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US990774A (en) * 1910-03-15 1911-04-25 John W P Reid Convertible core for building-blocks.
DE2808070A1 (de) 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US4616019A (en) 1984-01-26 1986-10-07 Abbott Laboratories Naphthyridine antibacterial compounds
DE3508816A1 (de) 1985-01-10 1986-07-10 Bayer Ag, 5090 Leverkusen 6,7-disubstituierte 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphtyridin-3-carbonsaeuren
US5126352A (en) 1985-06-13 1992-06-30 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4810708A (en) 1986-05-15 1989-03-07 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4988705A (en) * 1985-06-13 1991-01-29 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials
DE3804990A1 (de) * 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
JPH02124871A (ja) 1988-07-27 1990-05-14 Dainippon Pharmaceut Co Ltd １位が置換された複素環式カルボン酸アミド誘導体
CA2001203C (fr) 1988-10-24 2001-02-13 Thomas P. Demuth, Jr. Dithiocarbamoyl quinolones antimicrobiens
CA2012681A1 (fr) 1989-03-31 1990-09-30 Masayasu Okuhira Derives de la quinolone, procedes de preparation et agents antibacteriens les renfermant
JP2787713B2 (ja) * 1989-07-28 1998-08-20 富山化学工業株式会社 新規なイソチアゾローナフチリジンおよびイソチアゾローキノリン誘導体並びにそれらの塩
JP3012684B2 (ja) * 1989-12-08 2000-02-28 大日本製薬株式会社 チエノキノリン誘導体、チエノナフチリジン誘導体およびそれらの塩
GB9013615D0 (en) * 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
GB9023289D0 (en) 1990-10-25 1990-12-05 Ici Plc Herbicides
IL101860A0 (en) 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
EP0670320A4 (fr) 1992-12-01 1997-05-02 Green Cross Corp Derive de 1,8-naphthyridin-2-one et utilisation de ce derive.
DE4303657A1 (de) 1993-02-09 1994-08-11 Bayer Ag Neue Chinolon- und Naphthyridoncarbonsäurederivate
SI0787726T1 (en) 1994-06-14 2002-04-30 Dainippon Pharmaceutical Co., Ltd. Novel compound, process for producing the same, and antitumor agent
JP3242792B2 (ja) * 1994-08-05 2001-12-25 日本臓器製薬株式会社 ナフチリジニウム誘導体
MX9701600A (es) 1994-08-29 1997-05-31 Yamanouchi Pharma Co Ltd Derivados de naftiridina novedosos y composicion medicinal de los mismos.
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
MX9800922A (es) 1995-08-02 1998-05-31 Darwin Discovery Ltd Quinolonas y su uso terapeutico.
JP4323574B2 (ja) 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
EA003188B1 (ru) 1996-08-06 2003-02-27 Пфайзер Инк Замещенные пиридо- или пиримидосодержащие 6,6- или 6,7-бициклические производные
US6274592B1 (en) 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
US5994367A (en) * 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
CA2268190A1 (fr) 1997-08-06 1999-02-18 Suntory Limited Derive de 1-aryl-1,8-naphtylidine-4-one utilise en tant qu'inhibiteur de phosphodiesterase de type iv
GB9720052D0 (en) 1997-09-19 1997-11-19 Smithkline Beecham Plc Novel compounds
CN1156476C (zh) 1998-01-29 2004-07-07 第一三得利制药株式会社 作为ⅳ型磷酸二酯酶抑制剂的1-环烷基-1,8-二氮杂萘-4-酮衍生物
KR100286874B1 (ko) * 1998-03-04 2001-04-16 성재갑 보호된 4-아미노메틸-피롤리딘-3-온의 제조방법
EP1085846A2 (fr) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Inhibiteurs multiliaison de proteine triglyceride transferase microsomique
AU4694999A (en) * 1998-08-06 2000-02-28 Warner-Lambert Company Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
US6423721B1 (en) * 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
WO2000016774A1 (fr) 1998-09-18 2000-03-30 Senju Pharmaceutical Co., Ltd. Procede de solubilisation de l'acide pyridonecarboxylique, solubilisant a cet effet, preparations de solutions aqueuses contenant de l'acide pyridonecarboxylique et leur procede de production
JP2003500397A (ja) 1999-05-19 2003-01-07 スミスクライン ビーチャム パブリック リミテッド カンパニー Ｍｒｓ阻害剤としての２−ｎｈ−ピリドンおよびピリミドン
EP1276739A2 (fr) 2000-04-24 2003-01-22 Bristol-Myers Squibb Company Heterocycles utiles en tant qu'inhibiteurs de l'enzyme impdh
KR20040041177A (ko) * 2001-09-26 2004-05-14 바이엘 파마슈티칼스 코포레이션 당뇨병 치료제로서의 1,6-나프티리딘 유도체
US9885096B2 (en) 2012-02-24 2018-02-06 John Joseph Barsa Method and apparatus for high temperature production of metals

Also Published As

Publication number Publication date
IL160707A0 (en) 2004-08-31
JP2005504808A (ja) 2005-02-17
US20040209866A1 (en) 2004-10-21
GT200200194A (es) 2003-07-03
KR20040041178A (ko) 2004-05-14
US6964971B2 (en) 2005-11-15
CO5560611A2 (es) 2005-09-30
EP1432710A1 (fr) 2004-06-30
NO20041567L (no) 2004-05-11
PE20030549A1 (es) 2003-08-18
MA27079A1 (fr) 2004-12-20
US6677352B1 (en) 2004-01-13
RU2004112771A (ru) 2005-10-10
AR037503A1 (es) 2004-11-17
EP1432711A1 (fr) 2004-06-30
CA2461132A1 (fr) 2003-04-03
BR0212829A (pt) 2004-08-03
ZA200403064B (en) 2005-06-29
MXPA04002035A (es) 2004-06-07
US20040157875A1 (en) 2004-08-12
PL369531A1 (en) 2005-05-02
HRP20040317A2 (en) 2006-06-30
KR20040041177A (ko) 2004-05-14
UY27456A1 (es) 2003-04-30
PE20030601A1 (es) 2003-09-07
HRP20040309A2 (en) 2006-05-31
CN1578780A (zh) 2005-02-09
HUP0401889A2 (hu) 2005-01-28
JP2005504807A (ja) 2005-02-17
ZA200403063B (en) 2005-04-22
PL369567A1 (en) 2005-05-02
WO2003027113A1 (fr) 2003-04-03
IL160708A0 (en) 2004-08-31
US6900205B2 (en) 2005-05-31
US20040014751A1 (en) 2004-01-22
US20060189609A1 (en) 2006-08-24
WO2003027112A1 (fr) 2003-04-03
ECSP045084A (es) 2004-06-28
MA26344A1 (fr) 2004-10-01
GT200200191A (es) 2003-05-23
MXPA04002136A (es) 2005-03-07
RU2004112787A (ru) 2005-10-10
HN2002000275A (es) 2005-02-22
CO5560542A2 (es) 2005-09-30
AR037504A1 (es) 2004-11-17
BR0212864A (pt) 2004-08-17
ECSP045081A (es) 2004-06-28
UY27457A1 (es) 2003-04-30
CA2463039A1 (fr) 2003-04-03
CN1578781A (zh) 2005-02-09
HUP0402310A2 (hu) 2005-02-28
US7109196B2 (en) 2006-09-19

Similar Documents

Publication Publication Date Title
NO20041560L (no) 1,6-nafthyridinderivater som antidiabetiske midler
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
NO20035775L (no) 3-fluor-pyrrolidiner som anti-diabetesmidler
NO20043022L (no) 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
DE60216115D1 (de) BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
NO20015477L (no) 4,5,6,7-tetrahydroindazolderivater som antitumormidler
DK1414803T3 (da) Pyrazolylcarboxanilider som fungicider
NO20042955L (no) Substituerte fenylaftalener som estrogene midler
NO20041317L (no) Benzimidazolidinondenvater som muskarine midler
NO20020684L (no) 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler
DK1379522T3 (da) Dihydro-benzo(b)(1,4)diazeping-2-on-derivater som MGLUR2-antagonister I
NO20030929L (no) Guanidinobenzamider som MC4-R agonister
DK1456206T3 (da) Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
DK1455779T3 (da) Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
DK1429607T3 (da) Delta-1-pyrroliner som pesticider
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
NO20034527L (no) 3,7-diazabicyklo(3,3,1) formuleringer som antiarytmiforbindelser
DK1330458T3 (da) N-(1,2,4-triazoloazinyl)thiophensulfonamidforbindelser som herbicider
NO20034647D0 (no) Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
DK1231211T3 (da) Thiazolidindion-derivater som antidiabetika
DK1075471T3 (da) Idolylderivater som serotonerge midler
DK1263734T3 (da) 3-thiomethylpyrazoler som pesticider
NO20042980L (no) 3,4-dihydro-1H-isokinolin-2-yl-derivater